Cargando...
Dipeptidyl‐peptidase (DPP)‐4 inhibitors and glucagon‐like peptide (GLP)‐1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus
BACKGROUND: The projected rise in the incidence of type 2 diabetes mellitus (T2DM) could develop into a substantial health problem worldwide. Whether dipeptidyl‐peptidase (DPP)‐4 inhibitors or glucagon‐like peptide (GLP)‐1 analogues are able to prevent or delay T2DM and its associated complications...
Gardado en:
| Publicado en: | Cochrane Database Syst Rev |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
John Wiley & Sons, Ltd
2017
|
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6481586/ https://ncbi.nlm.nih.gov/pubmed/28489279 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD012204.pub2 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|